Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies, presented new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Boston. The data show that the company's next-generation suppressor tRNAs (sup-tRNAs) restore full-length dystrophin protein and achieve wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). Additionally, the sup-tRNAs provide durable rescue of full-length titin protein in a mouse model and functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM-TTNtv).
According to the announcement, Tevard's next-generation sup-tRNAs achieve approximately 100% restoration of full-length dystrophin in DMD models. The compact tRNA architecture enables flexible AAV packaging, precise dose control, and broad applicability for pathogenic nonsense mutations across diverse unmet medical needs. The presented programs highlight the versatility of the suppressor tRNA platform and its ability to restore native protein expression in a cell-specific, durable manner.
Duchenne muscular dystrophy is a severe genetic disorder caused by mutations in the dystrophin gene, leading to progressive muscle degeneration. Current treatments focus on managing symptoms, but Tevard's approach aims to correct the underlying genetic defect by suppressing premature stop codons. Similarly, TTN truncations are a common cause of dilated cardiomyopathy, a condition with limited therapeutic options. Tevard's data suggest that sup-tRNA therapy could restore full-length titin, potentially halting or reversing disease progression.
The company is advancing programs in muscular dystrophies, heart disease, and neurological disorders. For more information, visit Tevard's website. The full announcement, including downloadable images and bios, is available at the provided link.
